共 50 条
Modern Approach to Managing Vernal Keratoconjunctivitis
被引:8
作者:
Kumar, Sunil
[1
]
Gupta, Nitin
[2
]
Vivian, Anthony J.
[3
]
机构:
[1] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada
[2] W Suffok Hosp NHS Trust, Bury St Edmunds IP33 2QZ, Suffolk, England
[3] Addenbrookes Hosp, Cambridge Univ Hosp, Cambridge & Eye Treatment Ctr, Bury St Edmunds, Suffolk, England
关键词:
Vernal keratoconjunctivitis;
Giant papillae;
Mast cells stabilizer;
Selective antihistamine;
Dual-action drugs;
Corticosteroids;
Cyclosporine;
ALLERGIC CONJUNCTIVITIS;
TOPICAL CYCLOSPORINE;
LODOXAMIDE;
0.1-PERCENT;
MITOMYCIN-C;
EFFICACY;
EYEDROPS;
INJECTION;
SAFETY;
DEXAMETHASONE;
CROMOGLYCATE;
D O I:
10.1007/s11882-010-0101-7
中图分类号:
R392 [医学免疫学];
学科分类号:
100102 ;
摘要:
Vernal keratoconjunctivitis (VKC), an allergic inflammation of the conjunctiva affecting mainly children and adolescents, is categorized under the rubric of allergic conjunctivitis. Lack of uniform diagnostic and predefined staging criteria has been a bottleneck in formulating fixed guidelines to treat VKC. This lack of consensus among clinicians/researchers regarding diagnostic and grading standards has prevented us from making comparisons between the outcomes of different studies. To treat VKC, selection of a drug from many available options should be based on the duration and frequency of symptoms, grade and inflammation of giant papillae, and severity of corneal involvement. Consideration also should be given to the patient's specific needs. The basic tenet of treatment is optimal control of symptoms with a minimum of toxic side effects resulting from prolonged use of medication.
引用
收藏
页码:155 / 162
页数:8
相关论文
共 50 条